Effect and time course of topical ketotifen 0.025% and prednisolone sodium phosphate 0.5% on ocular dendritic cell density, morphology, and topographical distribution in participants with allergic conjunctivitis

The University of New South Wales0 个研究点目标入组 90 人开始时间: 2023年10月27日最近更新: 2023年11月6日

试验速览

暂无简介。

•1.Be at least 18 years of age or older.
•2. Positive result in the skin prick test.
•3. All participants must have current active allergic conjunctivitis symptoms (including itchy eyes or watery eyes or burning feeling or feeling like there is dirt or grit in your eyes) or signs (including redness or conjunctival chemosis or conjunctival papillae or conjunctival follicles), with or without a prior diagnosis of ocular allergy or hay fever.
•4. Able to read and comprehend English and give informed consent as demonstrated by signing a record of informed consent.

•1. Severe allergic conjunctivitis (reflective from the total symptoms scores of the Mini-RQLQ and OSDI questionnaires) including vernal keratoconjunctivitis and atopic keratoconjunctivitis.
•2. Negative result in the skin prick test.
•3. Severe asthma.
•4. Severe eczema.
•5. Past anaphylactic episode.
•6. Previous allergic reaction to any component of topical eyedrops used in this study including benzalkonium chloride preservative.
•7. Pregnant or breastfeeding/childbirth within three months from the date of recruitment.
•8. Regular contact lens wear (wearing contact lenses for at least two or more full days in a week).
•9. All other ocular surface diseases except allergic conjunctivitis.
•10. Ocular diseases that involve the cornea.
•11. Active intraocular inflammation.
•12. History of corneal refractive surgery.
•13. Systematic conditions affecting the ocular surface include diabetes, thyroid disorder, rheumatoid arthritis and Sjogren's syndrome.

发起方